Company aims to inhibit SARM1 enzyme to prevent

Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and regulating immune responses, which can further damage retinal cells. The company’s lead compound, ONL1204, is a first-in-class small molecule Fas inhibitor, designed to protect key retinal cells, including photoreceptors, from Fas-induced cell death, a primary cause of vision loss in a range of conditions. By targeting Fas signaling, ONL aims to address both the direct and inflammatory pathways leading to cell death, potentially offering a broad therapeutic benefit across a range of retinal diseases. The funding will be used to initiate a global Phase 2 study in patients suffering from geographic atrophy (GA) linked to dry age-related macular degeneration (AMD).…

Collaboration aims to empower health practitione

Coya Therapeutics is pioneering multi-pathway th

Elon Musk claims that experimental ‘Blindsight

Boosting cellular regeneration, reducing inflamm

Chai Discovery emerges with $30m in funding and

A new study considers epigenetic aging from a si

DoD-backed startup targets clinical trials of bi

Preventive health company appoints former Amazon

Ahead of Longevity Investors Conference, Matt Py

Chopra Foundation CEO on why longevity needs to

Company integrates generative biology, chemistry

Ahead of Longevity Investors Conference, Andrea

Research highlights novel gene therapy delivery

Project aims to scale production of induced plur

Longevity company builder Maximon spawns new ven

TimePie’s Hebe Chen spotlights the upcoming fi

Company eyes GLP-1 combination potential for ‘

A new study indicates that potassium isotope ana

Ahead of his appearance at Longevity Investors C

Food for the Brain develops pin-prick test that

New wellness brand introduces products inspired

Company targets organ transplant shortage after

Longevity biotech to become sector’s next publ

Company readies for Phase 2 studies after fronto

Berlin startup focuses on ‘whole genome’ ana

Australian-led research project lands $11.

Nadine Esposito on why focusing on finance and c

Study shows semaglutide has ‘far-reaching bene

Platform integrates health data from hundreds of

Cellular rejuvenation company aims to advance ne

Aging drug discovery conference demonstrates tha

Highly anticipated conference returns to Switzer

Companies file joint patents relating to synergi

Collaboration between LT, Founders Forum and NUS

Targeting inflammatory diseases, company gears u

As ARDD gets underway, Life Bio’s CEO explains

DdrC protein repairs broken DNA fragments, resto

Mary Lou Jepsen’s latest $100m venture leverag

More than 160 speakers to present as the world’s largest aging drug discovery conference opens its doors. In the glorious settings of The University of Copenhagen, the largest conference on aging in the biopharmaceutical industry kicks off its proceedings today, beginning a full week of sessions, speakers and workshops. The 11th annual Aging Research and Drug Discovery conference (ARDD) once again brings together the world’s leading authorities on the science of aging and how to target the aging process in humans to enable healthier and longer lives for all. In addition to ARDD’s always stellar academic lineup, the 2024 conference boasts an incredibly strong presence from leading biotech companies in the aging field, further boosted by the presence of pharma companies including Lilly, Lundbeck, Novartis, Regeneron and others. Another significant focus of this year’s event is on longevity medicine, with an entire track dedicated to the translation from basic science towards the clinic and the implications for practicing physicians. ARDD’s home is in Denmark at the University of Copenhagen. Alongside Insilico Medicine boss Alex Zhavoronkov, ARDD is chaired by University of Copenhagen professors Morten Scheibye-Knudsen and Daniela Bakula. “I’m extremely happy about the program – we have an incredible lineup…

Victoria Forest on how a new longevity city in G

ALZpath CEO on building a scalable Alzheimer’s

Veteran pharmaceutical executive Jean-Pierre Gar

Company intends to expand its network of longevi

Finnish company claims its test is the first to

Investment will fund VNA-318, Vandria’s lead t

Company taps into Pfizer’s Boulder team as it

New data-powered digital health platform Thrive

New research reveals that certain antidiabetic d